Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2022
>
Bayer will discontinue phase II development candidate eliapixant
Bayer will discontinue phase II development candidate eliapixant
Read also
Myeloma
Myeloma treatment HDP-101 put on FDA fast track
Evotec Announces Progress
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Evotec Announces Progress
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Tylenol (paracetamol)
Tylenol (paracetamol) fights autism claims, slams proposed FDA warning label as 'unsupported' by science
